K Malottki

925 total citations
17 papers, 725 citations indexed

About

K Malottki is a scholar working on Economics and Econometrics, Immunology and Statistics and Probability. According to data from OpenAlex, K Malottki has authored 17 papers receiving a total of 725 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Economics and Econometrics, 6 papers in Immunology and 4 papers in Statistics and Probability. Recurrent topics in K Malottki's work include Health Systems, Economic Evaluations, Quality of Life (9 papers), Statistical Methods in Clinical Trials (4 papers) and Genomics and Rare Diseases (3 papers). K Malottki is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (9 papers), Statistical Methods in Clinical Trials (4 papers) and Genomics and Rare Diseases (3 papers). K Malottki collaborates with scholars based in United Kingdom, Denmark and Sweden. K Malottki's co-authors include Lucinda Billingham, David Moore, Pelham Barton, Yen‐Fu Chen, A Fry-Smith, Neil Steven, Martin Connock, Laura Sawyer, Olalekan A. Uthman and Zhihong Liu and has published in prestigious journals such as PLoS ONE, The Lancet Oncology and BMJ Open.

In The Last Decade

K Malottki

17 papers receiving 703 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K Malottki United Kingdom 11 238 166 124 99 86 17 725
Liza Takiya United States 15 85 0.4× 267 1.6× 86 0.7× 137 1.4× 22 0.3× 47 888
Patrick Mollon United States 13 136 0.6× 249 1.5× 50 0.4× 77 0.8× 142 1.7× 33 740
I. Gilloteau United States 18 504 2.1× 169 1.0× 172 1.4× 302 3.1× 35 0.4× 48 998
Marisol E. Otero Netherlands 18 426 1.8× 104 0.6× 115 0.9× 277 2.8× 29 0.3× 25 821
Shiraz R. Gupta United States 15 700 2.9× 151 0.9× 237 1.9× 366 3.7× 34 0.4× 20 1.2k
Shahin Jamal Canada 21 229 1.0× 418 2.5× 53 0.4× 55 0.6× 81 0.9× 52 1.1k
Piet LCM van Riel Netherlands 15 180 0.8× 557 3.4× 47 0.4× 84 0.8× 40 0.5× 17 969
Shonda A. Foster United States 18 191 0.8× 197 1.2× 86 0.7× 41 0.4× 17 0.2× 41 782
Hüseyin Yüce United States 21 46 0.2× 87 0.5× 110 0.9× 64 0.6× 61 0.7× 87 1.1k
Jörg Ruof Germany 21 197 0.8× 635 3.8× 401 3.2× 27 0.3× 46 0.5× 67 1.4k

Countries citing papers authored by K Malottki

Since Specialization
Citations

This map shows the geographic impact of K Malottki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K Malottki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K Malottki more than expected).

Fields of papers citing papers by K Malottki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K Malottki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K Malottki. The network helps show where K Malottki may publish in the future.

Co-authorship network of co-authors of K Malottki

This figure shows the co-authorship network connecting the top 25 collaborators of K Malottki. A scholar is included among the top collaborators of K Malottki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K Malottki. K Malottki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Green, William H., et al.. (2024). Uncertainties in evaluating the health-related quality of life and disease burden of people with rare diseases and their caregivers in NICE HST submissions. Orphanet Journal of Rare Diseases. 19(1). 391–391. 2 indexed citations
2.
3.
Sawyer, Laura, et al.. (2020). Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year. Journal of Dermatological Treatment. 33(1). 204–218. 53 indexed citations
4.
Wright, Emily K., et al.. (2020). Assessing the Quality and Coherence of Network Meta-Analyses of Biologics in Plaque Psoriasis: What Does All This Evidence Synthesis Tell Us?. Dermatology and Therapy. 11(1). 181–220. 10 indexed citations
5.
Malottki, K, et al.. (2019). The Cancer Drugs Fund in Practice and Under the New Framework. PharmacoEconomics. 37(7). 953–962. 10 indexed citations
6.
7.
Billingham, Lucinda, K Malottki, & Neil Steven. (2016). Research methods to change clinical practice for patients with rare cancers. The Lancet Oncology. 17(2). e70–e80. 78 indexed citations
8.
Malottki, K, Sanjay Popat, Jonathan J Deeks, et al.. (2015). Problems of variable biomarker evaluation in stratified medicine research—A case study of ERCC1 in non-small-cell lung cancer. Lung Cancer. 92. 1–7. 10 indexed citations
9.
Malottki, K, Lucinda Billingham, Richard D Riley, & Jonathan J Deeks. (2015). Reviewing the evidence supporting predictive biomarkers in European medicines agency indications and contraindications using visual plots. Trials. 16(S2). 1 indexed citations
10.
Malottki, K, Mousumi Biswas, Jonathan J Deeks, et al.. (2014). Stratified medicine in European Medicines Agency licensing: a systematic review of predictive biomarkers. BMJ Open. 4(1). e004188–e004188. 15 indexed citations
11.
Billingham, Lucinda, K Malottki, & Neil Steven. (2012). Small sample sizes in clinical trials: a statistician’s perspective. Clinical Investigation. 2(7). 655–657. 20 indexed citations
12.
13.
Billingham, Lucinda, K Malottki, Mark G. Pritchard, & Neil Steven. (2011). Trials in rare diseases: the need to think differently. Trials. 12(S1). 2 indexed citations
14.
Connock, Martin, Sandy Tubeuf, K Malottki, et al.. (2010). Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis. Health Technology Assessment. 14(Suppl. 2). 1–10. 9 indexed citations
15.
Connock, Martin, Sandy Tubeuf, K Malottki, et al.. (2010). Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis. Health Technology Assessment. 14(Suppl 2). 1–10. 10 indexed citations
16.
17.
Malottki, K & H. W. Wiechmann. (2008). Akute lebensbedrohliche Bradykardie: Nahrungsmittelintoxikation durch türkischen Waldhonig. DMW - Deutsche Medizinische Wochenschrift. 121(30). 936–938. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Liza Takiya Breakdown of academic impact, for papers by Patrick Mollon Breakdown of academic impact, for papers by I. Gilloteau Breakdown of academic impact, for papers by Marisol E. Otero Breakdown of academic impact, for papers by Shiraz R. Gupta Breakdown of academic impact, for papers by Shahin Jamal Breakdown of academic impact, for papers by Piet LCM van Riel Breakdown of academic impact, for papers by Shonda A. Foster Breakdown of academic impact, for papers by Hüseyin Yüce Breakdown of academic impact, for papers by Jörg Ruof
Rankless by CCL
2026